“Rising Preference for Single-Injection Viscosupplementation Treatments”
- There is a growing preference for single-injection viscosupplementation therapies as they offer greater convenience and require fewer clinic visits compared to traditional multi-injection regimens
- For instance, Durolane is a widely used single-injection treatment that provides long-lasting knee pain relief with minimal disruption to patients’ routines
- The development of high-molecular-weight hyaluronic acid formulations has enabled effective treatment outcomes from a single dose, reducing the need for repeat administration
- For instance, Monovisc, a single-injection product, has gained FDA approval and is known for its strong efficacy in managing osteoarthritis symptoms
- These single-injection solutions are increasingly adopted in clinical practice due to their ability to reduce discomfort and streamline the patient experience
- Single-injection options contribute to better patient compliance and reduce overall healthcare costs by minimizing repeated appointments and associated expenses
- Healthcare providers and clinics favor these treatments for their ease of administration, especially in high-volume settings where time and resources are limited
